Reports
Millions in savings for patients & payers
As our portfolio expanded in 2025, CivicaScript delivered more than $16 million in savings. Since the launch of our first product in 2022, patients and payers have saved nearly $44 million.
Our 2025 Annual Savings Report highlights the value and growing impact of our unique business model. Together, our products created an estimated $82 million savings opportunity for patients and payers. As we continue our expansion to offer insulin and other biosimilars, CivicaScript remains focused on transforming the marketplace to make medicines affordable and available to everyone.
CivicaScript model delivers significant patient and payer savings. Learn more >
